Literature DB >> 6195273

Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.

S R Attridge, D Rowley.   

Abstract

The infant-mouse cholera model was used for evaluation of the immunoprophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae. The protective efficiency of antibodies to the nonlipopolysaccharide components of the 569B strain was much greater than that of antibodies to the lipopolysaccharide. Protective nonlipopolysaccharide antigens were not detected in two other strains, however; the possible basis for this restricted distribution was considered in light of studies from other laboratories. An investigation of the mechanism by which antibodies mediate protection in this model suggested that the critical property of protective antibodies is their capacity to block vibrio attachment directly.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195273     DOI: 10.1093/infdis/148.5.931

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

2.  Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens.

Authors:  K Richardson; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

3.  Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

Authors:  M M Levine; J B Kaper; D Herrington; G Losonsky; J G Morris; M L Clements; R E Black; B Tall; R Hall
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

4.  Nucleotide sequence encoding the mannose-fucose-resistant hemagglutinin of Vibrio cholerae O1 and construction of a mutant.

Authors:  V L Franzon; A Barker; P A Manning
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

5.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

6.  Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.

Authors:  C O Tacket; B Forrest; R Morona; S R Attridge; J LaBrooy; B D Tall; M Reymann; D Rowley; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera.

Authors:  R H Hall; G Losonsky; A P Silveira; R K Taylor; J J Mekalanos; N D Witham; M M Levine
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

8.  Detection of antibodies to toxin-coregulated pili in sera from cholera patients.

Authors:  Stephen R Attridge; Gun Wallerström; Firdausi Qadri; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

9.  Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae.

Authors:  S D Sears; K Richardson; C Young; C D Parker; M M Levine
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Major outer membrane proteins of Vibrio cholerae and their role in induction of protective immunity through inhibition of intestinal colonization.

Authors:  D K Sengupta; T K Sengupta; A C Ghose
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.